Chemical name: (17β)-3-Oxoandrost-4-en-17-yl propanoate
Formula: C22H32O3
Anabolic activity index: 100% (reference drug)
Androgenic activity index: 100% (reference drug)

INDUJECT-250 10 x 1ml AMP – ALPHA PHARMA

Description: INDUJECT-250 is a medication manufactured by Alpha Pharma. It is a blend of testosterone esters formulated for intramuscular injection. Each 1 ml ampoule typically contains a combination of four different testosterone esters, providing a total of 250 mg of testosterone per milliliter.

Indications: INDUJECT-250 is primarily indicated for the treatment of hypogonadism (low testosterone levels) in men. It may also be used in hormone replacement therapy (HRT) to supplement testosterone levels in individuals with deficient or absent endogenous testosterone production.

Composition: INDUJECT-250 contains a combination of testosterone esters, including but not limited to:

• Testosterone Propionate
• Testosterone Phenylpropionate
• Testosterone Isocaproate
• Testosterone Decanoate

The combination of these esters provides both immediate and sustained release of testosterone into the bloodstream after administration.

Mechanism of Action:

• Testosterone is the primary male sex hormone responsible for the development and maintenance of male secondary sexual characteristics, as well as the regulation of reproductive function and other physiological processes.
• In hypogonadal men, testosterone replacement therapy with INDUJECT-250 helps restore normal testosterone levels, leading to improvements in libido, energy levels, muscle mass, bone density, and overall well-being.

Administration:

• INDUJECT-250 is administered via intramuscular injection.
• The injection is typically given into the gluteal muscle (buttocks) or the deltoid muscle (shoulder), depending on healthcare provider preference and patient preference.

Dosage:

• The dosage of INDUJECT-250 may vary based on individual patient characteristics, including age, weight, and severity of testosterone deficiency.
• It is usually administered at intervals ranging from once every two weeks to once every four weeks, although dosing frequency may be adjusted based on patient response and serum testosterone levels.

Monitoring:

• Regular monitoring of serum testosterone levels, hematocrit, lipid profile, and prostate-specific antigen (PSA) levels is essential during testosterone replacement therapy with INDUJECT-250.
• Healthcare providers should also monitor for signs of testosterone excess or deficiency and adjust the dosage accordingly.

Side Effects: Common side effects of testosterone replacement therapy may include:

• Acne
• Oily skin
• Fluid retention
• Gynecomastia (breast enlargement)
• Testicular atrophy (shrinkage of the testicles)
• Mood swings
• Increased risk of cardiovascular events
• Suppression of natural testosterone production (particularly with long-term use)

Precautions:

• INDUJECT-250 should be used with caution in patients with a history of prostate disorders, cardiovascular disease, liver or kidney impairment, or breast cancer.
• It may interact with other medications, and patients should inform their healthcare provider about all the medications they are taking, including over-the-counter drugs and herbal supplements.

Consultation with Healthcare Professional:

• The use of INDUJECT-250 should be discussed thoroughly with a healthcare professional, typically an endocrinologist or urologist specializing in male reproductive health.
• Patients should inform their healthcare provider about their medical history, existing health conditions, and any medications they are taking before starting testosterone replacement therapy.

INDUJECT-250, manufactured by Alpha Pharma, is a testosterone replacement therapy indicated for the treatment of hypogonadism in men. Its use involves careful monitoring of testosterone levels and potential side effects to ensure optimal outcomes for patients requiring testosterone supplementation.